A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

December 20, 2019

Primary Completion Date

October 21, 2025

Study Completion Date

December 16, 2025

Conditions
Psoriasis
Interventions
DRUG

Apremilast

Apremilast dose will be increased from 20 mg BID to 30 mg BID for those subjects that reach a weight of 50 kg or more during the study

Trial Locations (50)

1000

Centre Hospitalier Universitaire Saint Pierre, Brussels

1200

Cliniques Universitaires Saint Luc, Brussels

3010

General University Hospital of Alicante, Alicante

9000

Universitair Ziekenhuis Gent, Ghent

13500

Cabinet du Docteur Ruer-Mulard Mireille, Martigues

20122

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan

28007

Hospital General Universitario Gregorio Maranon, Madrid

28009

Hospital Infantil Universitario Nino Jesus, Madrid

28041

Hospital 12 de Octubre, Madrid

28046

Hospital La Paz, Madrid

29425

Medical University of South Carolina, Charleston

31217

Skin Care Physicians of Georgia, Macon

31400

Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse

32256

Solutions Through Advanced Research Inc, Jacksonville

33173

Ciocca Dermatology, Miami

35020

Azienda Ospedaliera di Padova, Padua

39008

Hospital Marques de Valdecilla, Santander

45324

Wright State Physicians, Fairborn

46256

Dawes Fretzin Dermatology Group Inc, Indianapolis

72916

Johnson Dermatology Clinic, Fort Smith

78218

Driscoll Childrens Hospital, San Antonio

85016

Phoenix Childrens Hospital, Phoenix

91320

California Dermatology Institute, Thousand Oaks

92697

First OC Dermatology, Irvine

94304

Stanford University School of Medicine, Palo Alto

107076

State Scientific Center for Dermatovenereology and Cosmetology, Moscow

119071

Moscow Scientific Practical Center of Dermatology Venerology and Cosmetology, Moscow

119991

National Medical Research Center for Children Health, Moscow

150000

Yarosavl State Medical Academy, Yaroslavl

191123

Pierre Wolkenshtein Skin Diseases Clinic LLC, Saint Petersburg

194100

Saint Petersburg State Pediatric Medical University, Saint Petersburg

196158

LLC PiterKlinika, Saint Petersburg

350020

Clinical Dispensary of Dermatology and Venereology of Krasnodar Territory of the Ministry of Health, Krasnodar

420012

Republican Clinical Dermatology and Venerology Dispensary, Kazan'

450083

Bashkiria State Medical University, Ufa

454048

Chelyabinsk Regional Clinical Skin and Venereal Dispensary, Chelyabinsk

620076

Ural Scientific Research Institute of Dermatovenereology and Immunopathology, Yekaterinburg

630099

LLC Medical Center Zdorovaya Semiya, Novosibirsk

656038

Altai State Medical University, Barnaul

8410101

Soroka University Medical Center, Bear Sheva

53715-1375

University of Wisconsin Hospital and Clinics, Madison

T6G 2B7

Stollery Childrens Hospital, Edmonton

R3C 0N2

Winnipeg Clinic Dermatology Research, Winnipeg

A1C 2H5

Karma Clinical Trials, St. John's

M5A 3R6

AvantDerm, Toronto

100 34

Fakultni nemocnice Kralovske Vinohrady, Prague

120 00

Synexus Czech sro, Prague

09124

Azienda Ospedaliero Universitaria Di Cagliari, Cagliari

08950

Hospital Sant Joan de Deu, Esplugues de Llobregat

08916

Hopsital Germans Trias I Pujol, Badalona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY